海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
- Lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, France, Germany, Italy, Spain, Switzerland, United Kingdom, United States
- 2017-01-24
Authorised
- Study to Evaluate the Safety and Efficacy of CB-03-01 1% Cream Applied Twice-Daily for 12 Weeks in Subjects with Facial Acne Vulgaris
- facial acne vulgaris MedDRA version: 18.1 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Romania, United States
- 2015-10-26
Authorised
- Study to Evaluate the Safety and Efficacy of CB-03-01 1% Cream Applied Twice-Daily for 12 Weeks in Subjects with Facial Acne Vulgaris
- facial acne vulgaris MedDRA version: 18.0 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Bulgaria, Romania, United States
- 2015-10-07
Authorised
- A clinical study investigating the safety and tolerability of brexpiprazole in the Treatment of Subjects with Bipolar I Disorder
- Treatment of Manic Episodes Associated with Bipolar I Disorder MedDRA version: 20.0 Level: LLT Classification code 10068455 Term: Bipolar I disorder, hypomanic System Organ Class: 100000004873 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Bulgaria, Croatia, Poland, Romania, Serbia, Ukraine, United States
- 2018-01-12
Authorised
- Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients with Selected CD38+ Hematological Malignancies
- Haematological malignancy MedDRA version: 20.0 Level: PT Classification code 10066476 Term: Haematological malignancy System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Chile, Colombia, Finland, Greece, Israel, Italy, Mexico, Peru, Russian Federation, Spain, Turkey, Ukraine, United Kingdom, United States
- 2016-11-04
Authorised
- Comparison of the Safety and Efficacy of HOE901-U300 with Lantus in Children and Adolescents with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 19.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Brazil, Canada, Chile, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom, United States
- 2016-03-01
Authorised
- A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine, United States
- 2017-12-13
Authorised
- A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine, United States
- 2017-11-23
Authorised
- Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells
- mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Poland, Portugal, Russian Federation, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2018-01-18
Authorised
- An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.
- FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer MedDRA version: 18.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
- 2013-06-12